Clinical Study

D6070c00005-A Phase 1B/2 Study To Evaluate The Safety, Pharmacokinetics, And Clinical Activity Of Oleclumab (Medi9447) With Or Without Durvalumab In Combination With Chemotherapy In Subjects With Metastatic Pancreatic Ductal Adencarcinoma

Posted Date: Jun 11, 2019

  • Investigator: Olugbenga Olowokure
  • Specialties: Cancer, Oncology, Pancreatic Cancer
  • Type of Study: Drug

The goal of this study is to assess the safety and tolerability of oleclumab plus durvalumab in combination with chemotherapy administered in subjects with metastatic PDAC.


To Be Eligible: Patient Must Be 18 Years Of Age Or Older, Weight Over 35Kg, Diagnosed With Pancreatic Adenocarcinoma, Nonpregnant And Nonbreastfeeding No Other Anticancer Therapy Within 21 Days, No Venous Thrombosis, Heart Attack, Or Strokes Within Past 3 Months


Pancreatic Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.